Isis and Lilly renegotiate Affinitak production deal

- Last updated on GMT

Related tags: Eli lilly, Pharmacology

Isis Pharmaceuticals and Eli Lilly say they have reached a mutually
beneficial renegotiation of their manufacturing relationship for
cancer drug Affinitak

Isis Pharmaceuticals and Eli Lilly say they have reached a mutually beneficial renegotiation of their manufacturing relationship. Lilly has waived repayment of the $21 million (€18m) manufacturing loan it provided Isis to build a manufacturing facility for their cancer drug Affinitak (formerly called LY900003 and ISIS 3521).

Lilly has also agreed to allow Isis to use the facility to manufacture other drugs, including drugs in its pipeline and those arising out of research collaborations with partners, such as the broad antisense drug discovery collaboration with itself.

In exchange, Isis has agreed to release Lilly from its obligations contained in the supply agreement for Affinitak, an inhibitor of PKC-alpha in development for non-small cell lung cancer, including those associated with the purchase of additional product from Isis and paying for the costs of maintaining an idle manufacturing suite.

Isis completed the construction of a commercial-scale manufacturing facility for antisense oligonucleotides, initially dedicated to Affinitak and financed with the loan from Lilly, in February. The facility is capable of producing hundreds of kilograms antisense drugs a year.

Related news

Related products

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

The Effect of Tamping Force on Bi-Layer Tablets

The Effect of Tamping Force on Bi-Layer Tablets

JRS PHARMA | 15-Aug-2020 | Technical / White Paper

Formulation of bi-layer or multi-layer tablets enables the combination of two or more drugs that may be incompatible or maybe intended for delivery at...

Related suppliers

Follow us

Products

View more

Webinars